IDEXX Acquires CoVetAI, Buying the Exam-Room AI Scribe It Used to Just Benefit From

Every veterinary exam ends with paperwork nobody wants to write, and the race to own that stretch of software just claimed its biggest buyer yet. IDEXX Laboratories said Wednesday, September 16th, that it has acquired CoVetAI, the ambient-AI listening startup whose software drafts clinical notes from exam-room conversations, folding a category the diagnostics giant did not previously own into its practice-management stack. Terms were not disclosed.

IDEXX acquires CoVetAI's AI documentation platform

IDEXX Laboratories (Nasdaq: IDXX) announced Wednesday it has acquired CoVetAI Inc., known commercially as CoVet, an AI-native platform that transcribes veterinary exam-room conversations into structured clinical notes and streamlines client communication.

Mike Erickson, IDEXX's president and CEO, framed the deal around data volume rather than the note itself: "Veterinary practices are managing growing complexity and generating more information than ever before, and clinical teams need better ways to capture, connect, and use that information," he said in the announcement. CoVet co-founder and CEO Yannick Bloem said the company's mission "has been to use technology to give veterinary professionals more time back, for their patients and for themselves."

CoVet is young by comparison. Its own materials describe roughly 18 months of growth leading into a September 2025 funding round from Off Leash Capital, the Chicago Pacific Founders pet-focused fund. In that stretch it built a base of tens of thousands of veterinary professionals across the US, Canada, Australia, New Zealand and the UK, working with practices ranging from solo operators to 400-clinic groups, and staffed more than 60 employees, over 80% of them with direct clinical experience. IDEXX, by contrast, is a Nasdaq-listed, S&P 500-member diagnostics company with roughly 11,000 employees serving more than 10,000 clinics worldwide.

What CoVetAI's acquisition means for rival AI scribes

IDEXX has run the same playbook for years: place hardware or software into a clinic, then capture recurring revenue on everything that flows through it afterward. The Catalyst analyzer, installed in roughly 80,000 clinics, is the clearest example, and IDEXX spent this year adding to that base, most recently with a dual-species point-of-care cardiac test in August. Practice-management software has followed the same logic since IDEXX's 2021 purchase of ezyVet. CoVetAI extends that model one layer earlier, into the exam room itself, before a diagnosis or a test order even exists.

This isn't a cold entry into the category for IDEXX. In May, covering IDEXX's expansion of its Fecal Dx menu, this publication named CoVet directly as part of a wave of AI scribe products pulling more of the clinic visit into structured records, and noted that easier-to-place reference-lab orders from inside a SOAP note were "a tailwind IDEXX did not have to build." Five months later, IDEXX stopped relying on that tailwind and bought it outright.

The deal also reframes a crowded AI scribe market that has competed mostly on price and transcription accuracy, filled with independent vendors that own no diagnostics hardware, no reference lab, and no PIMS of their own. An ambient scribe wired into a platform that already handles billing, lab orders and inventory has a structural edge over one that has to integrate into somebody else's workflow. CoVet's practices, many running on PIMS products IDEXX doesn't own, now sit inside a company that also competes with Covetrus in the broader fight over veterinary software and distribution. Covetrus itself is mid-review on a $3.5 billion distribution merger with MWI Animal Health, a deal built on the same instinct to own more of the veterinary supply chain from a different angle.

For operators, the size of this particular deal matters less than its direction. The exam-room note used to be neutral territory, written into whatever PIMS a clinic happened to run. It's becoming another point where a platform vendor can bundle, price, or eventually steer access based on which ecosystem a practice is already paying into.

What happens to CoVet users on rival practice software

The immediate operator question is what happens to CoVet customers running a PIMS other than IDEXX's own, including Covetrus's AVImark and Impromed, or independents like Vetspire and Shepherd. IDEXX hasn't said whether it will keep CoVet's ambient-listening tool platform-agnostic or fold its best features into ezyVet and Cornerstone exclusively. The company has taken the open path with some prior software acquisitions and the walled-garden path with others, so the integration announcement, whenever it lands, is the signal that actually matters.

Pricing is the second open question, and IDEXX left it just as open with its cardiac diagnostics launch in August: no word yet on whether CoVet stays a paid standalone product, gets bundled free into existing PIMS contracts, or becomes a loss-leader that steers practices toward IDEXX's broader diagnostics menu. Any of the three changes the math differently for a solo practice weighing a scribe subscription against staff time.

The clearest thing to track is how competitors respond. Antech, the Mars-owned reference-lab and diagnostics rival, has historically lagged IDEXX's menu moves by six to eighteen months rather than matching immediately. Zoetis has no announced ambient-scribe product of its own. Covetrus, already absorbing an FTC antitrust review of its MWI merger, would invite its own regulatory scrutiny by attempting a comparable acquisition right now. Whether any of the three moves on an AI scribe startup within the next two quarters will say more about how seriously the category is taken industry-wide than this deal's undisclosed price tag does.

Source: IDEXX Laboratories via Business Wire